The disclosure relates to a compound 2-[(4S)-6-(4-Chlorophenyl)-1-methyl-8-(methyloxy)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide which is represented by structural formula (I) and a pharmaceutically acceptable salt thereof； which is suitable for use in the treatment of a chronic autoimmune and inflammatory condition and also for treating cancer selected from hematological including leukaemia, epithelial including lung, breast and colon carcinomas, midline carcinomas, mesenchymal, hepatic, renal and neurological tumours.
